EUVIMEDEUVIMED entdecken
Open Access

Cost-effectiveness of tenecteplase versus alteplase for stroke thrombolysis evaluation trial in the ambulance

Lan Gao iD, Mark Parsons, Leonid Churilov, Henry Zhao iD, Bruce Cv Campbell, Bernard Yan, Peter Mitchell, Skye Coote, Francesca Langenberg, Karen Smith, David Anderson, Michael Stephenson und 4 weitere

European Stroke Journal · 2023-06 · 8 (2) · 448-455

DOI: 10.1177/23969873231165086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Stroke Journal, online erschienen am 26.03.2023. Verfasst von Lan Gao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Deakin Health Economics, Institute of Health Transformation, Faculty of Health, Deakin University, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Stroke, Brain Ischemia, Ischemic Stroke. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenecteplase administered to patients with ischaemic stroke in a mobile stroke unit (MSU) has been shown to reduce the perfusion lesion volumes and result in ultra-early recovery. We now seek to assess the cost-effectiveness of tenecteplase in the MSU.

Methods

A within-trial (TASTE-A) economic analysis and a model-based long-term cost-effectiveness analysis were performed. This post hoc within-trial economic analysis utilised the patient-level data (intention to treat, ITT) prospectively collected over the trial to calculate the difference in both healthcare costs and quality-adjusted life years (QALYs, estimated from modified Rankin scale score). A Markov microsimulation model was developed to simulate the long-term costs and benefits.

Results

In total, there were 104 patients with ischaemic stroke randomised to tenecteplase ( n = 55) or alteplase ( n = 49) treatment groups, respectively in the TASTE-A trial. The ITT-based analysis showed that treatment with tenecteplase was associated with non-signficantly lower costs (A$28,903 vs A$40,150 ( p = 0.056)) and greater benefits (0.171 vs 0.158 ( p = 0.457)) than that for the alteplase group over the first 90 days post the index stroke. The long-term model showed that tenecteplase led to greater savings in costs (−A$18,610) and more health benefits (0.47 QALY or 0.31 LY gains). Tenecteplase-treated patients had reduced costs for rehospitalisation (−A$1464), nursing home care (−A$16,767) and nonmedical care (−A$620) per patient.

Conclusions

Treatment of ischaemic stroke patients with tenecteplase appeared to be cost-effective and improve QALYs in the MSU setting based on Phase II data. The reduced total cost from tenecteplase was driven by savings from acute hospitalisation and reduce need for nursing home care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StrokeBrain IschemiaIschemic StrokeHumansTissue Plasminogen ActivatorTenecteplaseCost-Benefit AnalysisFibrinolytic AgentsAmbulancesThrombolytic Therapy

Stichwörter der Autor:innen

Cost-effectivenessischaemic strokemobile stroke unittenecteplasethrombectomy

Substanzen

Tissue Plasminogen ActivatorTenecteplaseFibrinolytic Agents

Autor:innen und Institutionen

  • Deakin Health Economics, Institute of Health Transformation, Faculty of Health, Deakin University, Melbourne, VIC, Australia.
  • Department of Neurology, Liverpool Hospital, South Western Sydney Clinical School, University of New South Wales, Sydney NSW, Australia.
  • Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
  • Department of Radiology, at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC Australia.
  • School of Public Health, Monash University.
  • Ambulance Victoria, Melbourne, VIC, Australia.

ORCID-Profile: Lan Gao, Henry Zhao

Zitieren

APA

Gao, L., Parsons, M., Churilov, L., Zhao, H., Campbell, B. C., Yan, B., Mitchell, P., Coote, S., Langenberg, F., Smith, K., Anderson, D., Stephenson, M., Davis, S. M., Donnan, G., Easton, D., & Bivard, A. (2023). Cost-effectiveness of tenecteplase versus alteplase for stroke thrombolysis evaluation trial in the ambulance. European Stroke Journal, 8(2), 448-455. https://doi.org/10.1177/23969873231165086

Vancouver

Gao L, Parsons M, Churilov L, Zhao H, Campbell BC, Yan B, et al. Cost-effectiveness of tenecteplase versus alteplase for stroke thrombolysis evaluation trial in the ambulance. European Stroke Journal. 2023;8(2):448-455. doi:10.1177/23969873231165086

BibTeX
@article{Gao2023,
  author = {Gao, Lan and Parsons, Mark and Churilov, Leonid and Zhao, Henry and Campbell, Bruce Cv and Yan, Bernard and Mitchell, Peter and Coote, Skye and Langenberg, Francesca and Smith, Karen and Anderson, David and Stephenson, Michael and Davis, Stephen M and Donnan, Geoffrey and Easton, Damien and Bivard, Andrew},
  title = {Cost-effectiveness of tenecteplase versus alteplase for stroke thrombolysis evaluation trial in the ambulance},
  journal = {European Stroke Journal},
  year = {2023},
  volume = {8},
  number = {2},
  pages = {448--455},
  doi = {10.1177/23969873231165086}
}
Kostenlos starten →